LALPATHLAB Dr. Lal Path Labs Q3 FY25 results (Oct–Dec 2024) and concall
Dr Lal Pathlabs delivered a robust Q3 FY25 performance characterized by double-digit revenue growth and significant margin stability despite inflationary pressures and no price hikes. The company is successfully leveraging its 'Swasthfit' bundling strategy to drive higher realizations per patient and is seeing a strong recovery in its core Delhi NCR market. Management is focused on geographical expansion into Tier-3/4 towns and strengthening its presence in the South and West regions.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 660 | 597 |
| EBITDA | 202 | 154 |
| Net profit | 131 | 98 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
